Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data
Read More Pharma Industry News Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data Bristol Myers Squibb’s Camzyos cleared a key adolescent Phase 3 hurdle in oHCM. Read what the SCOUT-HCM data could mean for growth and competition. byVenkateshMarch 30, 2026